Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System

Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System

Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world's new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of the new cases and 17.4% of the deaths from non-Hodgkin lymphoma. Therefore, improving lymphoma diagnosis and treatment levels is a critical challenge in China. To gain a deeper understanding of the current status and progress of lymphoma diagnosis and treatment in China, Hematology Frontier interviewed Dr. Luguo Qiu, Director of the Lymphoma Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , for an in-depth analysis of this topic.
World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

September 4 marks "World Leukemia Day," an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called "blood cancer," is a complex disease with high treatment costs and the risk of relapse, placing a heavy burden on many families. However, through awareness and action on this day, we aim to break the silence and helplessness, and collectively ignite a beacon of hope for leukemia patients.
To foster interdisciplinary integration in hematology, accelerate the innovation and translation of scientific research, promote high-quality development of the discipline

To foster interdisciplinary integration in hematology, accelerate the innovation and translation of scientific research, promote high-quality development of the discipline

To foster interdisciplinary integration in hematology, accelerate the innovation and translation of scientific research, promote high-quality development of the discipline, and contribute to the Healthy China Initiative, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) will be held from January 3rd to 5th, 2025, in Tianjin.
ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment

ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract #1002), offering new perspectives for future therapeutic strategies. To provide deeper insights, Hematology Frontier invited Professor Duan for an in-depth discussion on his research.
ASH 2024 | Professor Jerald Radich:Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

ASH 2024 | Professor Jerald Radich:Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer Center provided an in-depth analysis of how mutations, clonal architecture, and disease evolution influence treatment response, resistance, and relapse.To clarify the complex relationship between MRD and clonal dynamics, Hematology Frontier has compiled key insights from this discussion.
2024 CCHIO & CACA 40th Anniversary: A Landmark Event in Cancer Prevention and Treatment

2024 CCHIO & CACA 40th Anniversary: A Landmark Event in Cancer Prevention and Treatment

On November 14, 2024, the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) and the 40th Anniversary of the China Anti-Cancer Association (CACA) commenced at the Xi’an International Conference Center. Themed “CACA at 40: Carrying Forward and Innovating,” the event brought together medical experts, patient advocates, and leaders from various sectors to advance the fight against cancer.